KR20240053620A - 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법 - Google Patents

항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법 Download PDF

Info

Publication number
KR20240053620A
KR20240053620A KR1020247010680A KR20247010680A KR20240053620A KR 20240053620 A KR20240053620 A KR 20240053620A KR 1020247010680 A KR1020247010680 A KR 1020247010680A KR 20247010680 A KR20247010680 A KR 20247010680A KR 20240053620 A KR20240053620 A KR 20240053620A
Authority
KR
South Korea
Prior art keywords
subject
seq
dose
administered
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247010680A
Other languages
English (en)
Korean (ko)
Inventor
로버트 고든
이샤니 랜드리
팔라비 사츠데브
데이비드 버벨
린 크레이머
미치오 가네키요
아키히코 고야마
채드 스완슨
마이클 이리재리
준 캐플로
쇼바 다다
라리사 레이더만
세이이치 하야토
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20240053620A publication Critical patent/KR20240053620A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020247010680A 2021-08-30 2022-08-29 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법 Pending KR20240053620A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163260730P 2021-08-30 2021-08-30
US63/260,730 2021-08-30
US202263306050P 2022-02-02 2022-02-02
US63/306,050 2022-02-02
US202263269389P 2022-03-15 2022-03-15
US63/269,389 2022-03-15
US202263269463P 2022-03-16 2022-03-16
US63/269,463 2022-03-16
US202263364619P 2022-05-12 2022-05-12
US63/364,619 2022-05-12
PCT/US2022/041926 WO2023034230A1 (en) 2021-08-30 2022-08-29 Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20240053620A true KR20240053620A (ko) 2024-04-24

Family

ID=83438517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247010680A Pending KR20240053620A (ko) 2021-08-30 2022-08-29 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법

Country Status (9)

Country Link
US (1) US20240352109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4395821A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532438A (cg-RX-API-DMAC7.html)
KR (1) KR20240053620A (cg-RX-API-DMAC7.html)
AU (1) AU2022338055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230148A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024002567A (cg-RX-API-DMAC7.html)
TW (1) TW202328178A (cg-RX-API-DMAC7.html)
WO (1) WO2023034230A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL324807A (en) * 2023-06-09 2026-01-01 Eisai R&D Man Co Ltd Treatment methods using anti-Abeta protofibril antibody
CN116953261B (zh) * 2023-08-10 2024-09-17 浙江格物致知生物科技有限公司 一种检测脓毒症的联检试剂盒及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
KR102630042B1 (ko) * 2016-10-27 2024-01-29 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물

Also Published As

Publication number Publication date
AU2022338055A1 (en) 2024-02-29
TW202328178A (zh) 2023-07-16
MX2024002567A (es) 2024-03-20
EP4395821A1 (en) 2024-07-10
JP2024532438A (ja) 2024-09-05
WO2023034230A1 (en) 2023-03-09
CA3230148A1 (en) 2023-03-09
US20240352109A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
JP2025160337A (ja) アルツハイマー病を治療する方法
WO2023140269A1 (en) Treatment of autoimmune encephalitis with satralizumab
US20250163135A1 (en) Biomarkers for alzheimer's disease treatment
CN118591389A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
US20250377367A1 (en) Methods of treatment using p-tau181 level
AU2023208107A1 (en) Composition comprising an anti-Αβ protofibril antibody and a beta- secretase BACE1 inhibitor for the treatment of Alzheimer's disease
TW202430554A (zh) 使用tau PET水平之治療方法
US20240352109A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
KR20240118915A (ko) 항-타우 항체 조성물, 투여 형태 및 방법
TW202434290A (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
TW202313111A (zh) 治療阿茲海默症之方法
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000